News

Instant vaccine in the making
Enlarge image

ResearchGermany

Instant vaccine in the making

26.11.2012 - Immunologists from Germany prove that messenger RNA vaccines work in mice, ferrets and pigs. Translation to humans would speed up flu control.

The idea sounds compelling: Instead of injecting peptide parts or complete proteins to trigger immune reactions, future vaccines could consist of messenger RNA molecules. Scientists from the Friedrich-Loeffler-Institut and the biotech enterprise CureVac GmbH (both from Tübingen, Germany) as well as from a branch of Friedrich-Loeffler-Institut on an island in the Baltic Sea near Greifswald, showed that immunisation with mRNA works thus far in mice, ferrets and pigs. The corresponding study was published online on 25 November by Nature Biotechnology. Lead author Lothar Stitz from Greifwald and colleagues report that the resulting immune responses were similar or even stronger than those provoked by commercially available vaccines.

Producing conventional vaccines is a time-consuming process. If Stitz’ approach also works in humans, flu vaccines could be designed and made within weeks instead of months. Hence, pandemics could be brought under control much more easily. What is more, mRNA vaccines in general are characterised by superior stabilities at high temperatures and by improved efficacy in young and old mice. These features could make a difference as it is mostly the elderly and children who suffer most from flu casualties.

The results strengthen German Curevac GmbH, the manufacturer of mRNA-coded antigens. Only in September, the biotech set a German record by closing the biggest financing round of a German biotech ever (€80m).

© eurobiotechnews.eu/ml

FundingEU

11.07.2014 Among the seven newly launched Joint Technology Initiatives (JTI) of Horizon2020 are two with deep roots in biotech: IMI is going into its second round while the newly established Bio-based Industries partnership invests in bioeconomy.

Stock marketNetherlandsUKBelgium

10.07.2014 Not one but two biopharma companies are seeking entry into the stock market: After Abzena raised €25m in an IPO earlier this week, Argen-x has followed suit and sold shares worth €40m.

M&AUKIreland

08.07.2014 Abbvie is determined to bring home British rare disease specialist Shire in a merger worth £30.1bn (€37.9bn). So far, Shire has rejected all offers from the US company.

M&ASwitzerland

04.07.2014 Genentech, a member of Swiss Roche Group, is set to acquire US-biotech Seragon Pharmaceuticals Inc. With the move, Genentech will obtain the rights to investigational breast cancer treatments.

M&AFranceGermany

03.07.2014 Nicox S.A. is stretching beyond the European market: The French eye health specialist is set to acquire Aciex Therapeutics Inc., a US-based pharma company with several ophthalmic therapeutics nearing market maturity.

FinanceBelgium

01.07.2014 Belgian antibody specialist Ablynx has raised €41.7m through a private placement of new shares and plans on boosting their range of nanobodies in development.

BioeconomyBelgiumUK

30.06.2014 Building on a £1.2m financing round, Celtic Renewables partners with a Belgian pilot plant to bring its bio-fuel made from whisky production residue to an industrial scale.

ConventionEUUK

25.06.2014 Sun, celebrities and a scandal - the world’s largest biotech convention is getting off to an explosive start in San Diego, California.

InvestmentGermanyNetherlands

24.06.2014 Bayer Healthcare is getting back into gene therapy with a US$252m deal aimed at the development of a haemophilia A treatment.

InvestmentNetherlands

20.06.2014 Tomtom founder Pieter Geelen invests in Dutch biotech Ocello, the company behind a 3D mapping technology used for predicting drug behaviour in patients.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • SERODUS (N)3.05 NOK7.02%
  • SUMMIT (UK)4.03 GBP3.87%
  • DEINOVE (F)13.32 EUR2.46%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • ALMIRALL (E)11.07 EUR-7.13%

TOP

  • SANTHERA (CH)70.65 CHF114.1%
  • CELLECTIS (F)13.54 EUR112.6%
  • ADDEX (CH)4.54 CHF108.3%

FLOP

  • THROMBOGENICS (B)8.51 EUR-51.5%
  • MERCK KGAA (D)63.67 EUR-50.6%
  • VERONA PHARMA (UK)1.20 GBP-42.9%

TOP

  • SANTHERA (CH)70.65 CHF3111.4%
  • GW PHARMACEUTICALS (UK)443.50 GBP843.6%
  • PAION (D)2.71 EUR310.6%

FLOP

  • CYTOS (CH)0.24 CHF-93.1%
  • EVOCUTIS (UK)0.21 GBP-92.6%
  • THROMBOGENICS (B)8.51 EUR-73.6%

No liability assumed, Date: 12.07.2014